Monomethylvaline compounds capable of conjugation to ligands

Details Monomethylvaline compounds capable of conjugation to ligands Monomethylvaline compounds capable of conjugation to ligands

2011-06-21

2011-06-21

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S019400, C514S019500, C514S019600, C424S178100, C424S179100, C424S181100, C530S391100

Reexamination Certificate

active

07964566

ABSTRACT:
Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

REFERENCES:
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4943628 (1990-07-01), Rosen et al.
patent: 4978744 (1990-12-01), Petit et al.
patent: 5169774 (1992-12-01), Frankel et al.
patent: 5286637 (1994-02-01), Veronese et al.
patent: 5410024 (1995-04-01), Petit et al.
patent: 5629197 (1997-05-01), Ring et al.
patent: 5635483 (1997-06-01), Pettit et al.
patent: 5654399 (1997-08-01), Sakakibara et al.
patent: 5767237 (1998-06-01), Sakakibara et al.
patent: 5780588 (1998-07-01), Pettit et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5840699 (1998-11-01), Sakakibara et al.
patent: 6004934 (1999-12-01), Sakakibara et al.
patent: 6048720 (2000-04-01), Dalborg et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6054561 (2000-04-01), Ring
patent: 6124431 (2000-09-01), Sakakibara et al.
patent: 6214345 (2001-04-01), Firestone et al.
patent: 6407213 (2002-06-01), Carter et al.
patent: 6569834 (2003-05-01), Pettit et al.
patent: 6620911 (2003-09-01), Petit et al.
patent: 6639055 (2003-10-01), Carter et al.
patent: 6884869 (2005-04-01), Senter et al.
patent: 7091186 (2006-08-01), Senter et al.
patent: 7375078 (2008-05-01), Feng
patent: 7553816 (2009-06-01), Senter et al.
patent: 7659241 (2010-02-01), Senter et al.
patent: 7662387 (2010-02-01), Law et al.
patent: 7754681 (2010-07-01), Feng
patent: 7829531 (2010-11-01), Senter et al.
patent: 7837980 (2010-11-01), Alley et al.
patent: 7851437 (2010-12-01), Senter et al.
patent: 2002/0001587 (2002-01-01), Erickson et al.
patent: 2003/0083263 (2003-05-01), Doronina et al.
patent: 2003/0096743 (2003-05-01), Senter et al.
patent: 2003/0130189 (2003-07-01), Senter et al.
patent: 2004/0018194 (2004-01-01), Francisco et al.
patent: 2004/0235068 (2004-11-01), Levinson
patent: 2005/0009751 (2005-01-01), Senter et al.
patent: 2005/0106644 (2005-05-01), Cairns et al.
patent: 2005/0107595 (2005-05-01), Cairns et al.
patent: 2005/0113308 (2005-05-01), Senter et al.
patent: 2005/0232929 (2005-10-01), Kadkhodayan et al.
patent: 2005/0238650 (2005-10-01), Crowley et al.
patent: 2005/0256030 (2005-11-01), Feng
patent: 2005/0272665 (2005-12-01), Schmid et al.
patent: 2006/0073152 (2006-04-01), Dennis
patent: 2006/0074008 (2006-04-01), Senter et al.
patent: 2006/0128970 (2006-06-01), Bliss et al.
patent: 2006/0182751 (2006-08-01), Gazzard et al.
patent: 2006/0233794 (2006-10-01), Law et al.
patent: 2007/0092520 (2007-04-01), Dennis et al.
patent: 2007/0134243 (2007-06-01), Gazzard et al.
patent: 2007/0212356 (2007-09-01), Chen et al.
patent: 2114156 (1994-07-01), None
patent: 06-234790 (1994-08-01), None
patent: 09-77791 (1997-03-01), None
patent: WO 99/35164 (1999-07-01), None
patent: WO 01/18032 (2001-03-01), None
patent: WO 02/088172 (2002-11-01), None
patent: WO 03/008378 (2003-01-01), None
patent: WO 03/034903 (2003-05-01), None
patent: WO 03/043583 (2003-05-01), None
patent: WO 2004/010957 (2004-02-01), None
patent: WO 2004/032828 (2004-04-01), None
patent: WO 2004/073656 (2004-09-01), None
patent: WO 2006/034488 (2006-03-01), None
patent: WO 2006/083936 (2006-08-01), None
patent: WO 2007/001851 (2007-01-01), None
patent: WO 2007/109567 (2007-09-01), None
Doronina et al., “Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity,”Bioconjugate Chem., 17:114-124 (2006).
Doronina et al., “Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy,” SciFinder search result, abstract of paper from 228th ACS National Meeting held in Philadelphia, PA, Aug. 22-26, 2004.
Gaertner & Offord, “Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins.”Bioconj. Chem.7(1): 38-44 (1996).
Genet, J. P., “Recent studies on asymmetric hydrogenation. New catalysts and synthetic applications in organic synthesis,”Pure Appl. Chem., 74(1):77-83 (2002).
Inada et al., “Modification of proteins with polyethylene glycol derivatives.”Methods Enzymol.242: 65-90 (1994).
Miyazaki et al., “Synthesis and Antitumor Activity of Novel Dolastatin 10 Analogs,”Chem. Pharm. Bull., 43(10):1706-1718 (1995).
Natsume et al., “Characterization of the Interaction of TZT-1027, a Potent Antitumor Agent, with Tubulin,”Jpn. J. Cancer, 91:737-747 (2000).
Petit et al., “Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications,”Anti-Cancer Drug Design, 10:529-544 (1995).
Petit et al., “Specific Activities of Dolastatin 10 and Peptide Derivatives againstCryptococcus neoformans,” Antimicrobial Agents and Chemotherapy, 42(11):2961-2965 (1998).
Petit et al., “A Cobalt—Phosphine Complex Directed Reformatsky Approach to a Stereospecific Synthesis of the Dolastatin 10 Unit Dolaproine (Dap)1,”J. Org. Chem., 66:8640-8642 (2001).
Thornber, “Isosterism and molecular modification in drug design.”Chem. Soc. Rev.8(4): 563-580 (1979).
Vippagunta et al., “Crystalline solids.”Adv. Drug Delivery Rev.48: 3-26 (2001).
Woyke et al., “Effect of auristatin PHE on microtube integrity and nuclear localization inCryptococcus neoformans,” Antimicrobial Agents and Chemotherapy, 46(12):3802-3808 (2003).
International Search Report of Oct. 2, 2006 for PCT application PCT/US04/38392, which corresponds to the parent U.S. Appl. No. 10/983,340.
Written Opinion of Oct. 2, 2006 for PCT application PCT/US04/38392, which corresponds to the parent U.S. Appl. No. 10/983,340.
Alley et al., “Controlling the location of drug attachment in antibody-drug conjugates,”Proceedings of the AACR, vol. 45, abstract # 627 (2004).
Afar et al., “Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer,”Molecular Cancer Therapeutics, 3(8):921-932 (2004).
Bhaskar et al., “E-Selectin Up-Regulation Allows for Targeted Drug Delivery in Prostate Cancer,”Cancer Research, 63:6387-6394 (2003).
Carter, “Improving the Efficacy of Antibody-Based Cancer Therapies, ” Nature Reviews 1:118-129 (2001).
Dillman, “Monoclonal Antibodies for Treating Cancer,”Annals of Internal Medicine111:592-603 (1989).
Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy,”Nature Biotechnology, 21(7):778-784 (2003) + Erratum,Nature Biotechnology, 21(8):941 (2003).
Emery et al., “Humanized monoclonal antibodies for therapeutic applications,”Exp. Opin. Invest. Drugs3(3):241-251 (1994).
Francisco et al., “cAC10-veMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity,”Blood, 102(4):1458-1465 (2003).
Hamblett et al., “Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate,”Proceedings of the AACR, vol. 45, abstract # 624 (2004).
Kline et al., “Novel Antitumor Prodrugs Designed for Activation by Matrix Metalloproteinases-2 and -9,”Molecular Pharmaceutics, 1(1):9-22 (2004).
Klussman et al., “Secondary mAb—vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway,”Bioconjug Chem., 15(4):765-773 (2004).
Law et al., “CD70 is expressed on renal cell carcinoma and is a potential target for tumor cell elimination by antibody-drug conjugates,”Proceedings of the AACR, vol. 45, abstract # 625 (2004).
Mao et al., “EphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer,”Cancer Research, 64:781-788 (2004).
Meyer et al., “Recent Advances in Antibody Drug Conjugates for Cancer T

Affiliated with

Also associated with

Rating

Monomethylvaline compounds capable of conjugation to ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Monomethylvaline compounds capable of conjugation to ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monomethylvaline compounds capable of conjugation to ligands will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2702219